Prolific Machines Raises $50 Million in Series B2 Funding

Prolific Machines, a biotechnology firm based in Emeryville, California, has announced the successful closing of a $50 million Series B2 funding round. This latest investment was led by Atoms & Bits, with participation from Nant Capital. The funding was officially announced on October 13, 2026.

About Prolific Machines

Prolific Machines specializes in simplifying complex protein production. The company provides a next-generation expression system designed for the development of advanced therapeutics. By integrating optogenetics-enabled solutions, Prolific Machines aims to enhance biologics development and manufacturing processes, focusing on delivering high yields, superior on-target quality, and precise process control.

Leadership and Vision

The company is co-founded by Declan Jones, who serves as the Chief Innovation Officer, Deniz Kent, Ph.D., the Chief Executive Officer, and Max Huisman, the Chief Technology Officer. Their leadership is pivotal in steering the company towards leveraging cutting-edge biotechnology to address current challenges in therapeutic protein production.

Strategic Use of Funds

While specific plans for the use of the newly acquired funds were not disclosed, it can be anticipated that the investment will support Prolific Machines in further advancing its technology and possibly expanding its market reach. Such developments are crucial as the demand for efficient and reliable biologics manufacturing solutions continues to rise.

Location

The company's operations are based in Emeryville, California, United States, where it continues to innovate at the intersection of biotechnology and therapeutic development.

Investors

The round was led by Atoms & Bits, a growth-stage investment firm. Nant Capital also participated, bringing its experience in health and life sciences to support Prolific Machines' mission.

This funding round marks a significant step for Prolific Machines as it continues to refine its expression systems and contribute to the broader field of biotechnology.